OTCMKTS:SRNE Sorrento Therapeutics (SRNE) Stock Price, News & Analysis $0.0003 0.00 (0.00%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Sorrento Therapeutics Stock (OTCMKTS:SRNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sorrento Therapeutics alerts:Sign Up Key Stats Today's Range$0.0003▼$0.000450-Day Range N/A52-Week Range$0.0001▼$0.0150Volume16,472 shsAverage Volume80,180 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sorrento Therapeutics, Inc. is a biotechnology company focused on developing therapies for cancer, chronic pain and other serious medical conditions. The company has historically pursued treatments based on antibody therapeutics, cellular therapies and targeted drug-delivery technologies, with research and development centered primarily in the United States. Sorrento’s development programs have included immuno-oncology and chimeric antigen receptor T-cell (CAR-T) therapies, as well as its Sofusa lymphatic drug-delivery platform. The company has also developed resiniferatoxin (RTX), an investigational non-opioid treatment designed to target severe, chronic pain. Other programs have addressed solid tumors, hematologic cancers and infectious diseases, including COVID-19-related diagnostics and therapeutics. Founded in 2009 and headquartered in San Diego, California, Sorrento has operated primarily as a clinical-stage biotechnology company rather than a commercial pharmaceutical business. Dr. Henry Ji, a co-founder, has historically served as chairman and chief executive officer. Sorrento filed for Chapter 11 bankruptcy protection in 2023, and its securities have since undergone significant changes from their former Nasdaq listing. AI Generated. May Contain Errors. Read More Receive SRNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRNE Stock News HeadlinesSorrento Therapeutics (SRNE) Projected to Release Earnings on FridayOctober 30, 2026 | americanbankingnews.comSorrento Therapeutics Inc (SRNE) - Investing.comJuly 3, 2025 | investing.comThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.November 3 at 1:00 AM | Brownstone Research (Ad)SRNE Sorrento Therapeutics, Inc. - Seeking AlphaJune 29, 2025 | seekingalpha.comSorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | BenzingaApril 19, 2025 | benzinga.comScilex says bankruptcy court extends lockup period on shares of Scilex dividendJanuary 31, 2025 | markets.businessinsider.comSorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO saysAugust 20, 2024 | msn.comSorrento Therapeutics Inc (SRNE)May 25, 2024 | investing.comSee More Headlines SRNE Stock Analysis - Frequently Asked Questions How have SRNE shares performed this year? Sorrento Therapeutics' stock was trading at $0.0026 on January 1st, 2026. Since then, SRNE stock has decreased by 88.5% and is now trading at $0.0003. How do I buy shares of Sorrento Therapeutics? Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sorrento Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sorrento Therapeutics investors own include NIO (NIO), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Novavax (NVAX). Company Calendar Today11/03/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:SRNE Previous SymbolNASDAQ:SRNE CIK850261 Webwww.sorrentotherapeutics.com Phone(858) 203-4100Fax858-210-3759Employees949Year Founded2006Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data Beta0.12 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:SRNE) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
